Association of Timing of Plasma Transfusion With Adverse Maternal Outcomes in Women With Persistent Postpartum Hemorrhage

Dacia D. C. A. Henriquez*, Camila Caram-Deelder, Saskia le Cessie, Joost J. Zwart, Jos J. M. van Roosmalen, Jeroen C. J. Eikenboom, Cynthia So-Osman, Leom. G. van de Watering, Jaap Jan Zwaginga, Ankie W. M. M. Koopman-van Gemert, Kitty W. M. Bloemenkamp, Johanna G. van der Bom, Cock M. C. Bank, Yvette S. Snuif-de Lange, Adriaan J. van Gammeren, Dimitri N. M. Papatsonis, Harriet Klinkspoor, Marjolein Kok, Bauke A. de Boer, Josje LangenveldMathie P. G. Leers, Jart H. C. Diris, Rene D. Kok, Paula Engbers, Marjo J. C. P. Hanssen, Wim J. van Wijngaarden, Daniela H. Schippers, Josw. J. van der Stappen, Tom H. M. Hasaart, Daan H. van de Kerkhof, Jacques B. de Kok, Gijs A. van Unnik, Wouter Kortlandt, Nicow. E. Schuitemaker, Friso M. C. Delemarre, Hans L. P. van Duijnhoven, Hans J. Duvekot, Sietske Hogenboom, Gunilla Kleiverda, Mylene J. W. van Etten-van Hulst, Karin Pagano Mirani-Oostdijk, Corine van Kampen, Martin J. N. Weinans, Henk J. Adriaanse, Jeffrey F. W. Keuren, Yvonne M. C. Henskens, Liesbeth H. C. J. Scheepers, Marjolein J. de Vries, Lenneke Prinzen, TeMpOH-1 Research Group

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


IMPORTANCE Early plasma transfusion for women with severe postpartum hemorrhage (PPH) is recommended to prevent coagulopathy. However, there is no comparative, quantitative evidence on the association of early plasma transfusion with maternal outcomes.

OBJECTIVE To compare the incidence of adverse maternal outcomes among women who received plasma during the first 60 minutes of persistent PPH vs women who did not receive plasma for similarly severe persistent PPH.

DESIGN, SETTING, AND PARTICIPANTS This multicenter cohort study used a consecutive sample of women with persistent PPH, defined as PPH refractory to first-line measures to control bleeding, between January 1, 2011, and January 1, 2013. Time-dependent propensity score matching was used to select women who received plasma during the first 60 minutes of persistent PPH and match each of them with a woman who had shown the same severity and received the same treatment of PPH but who had not received plasma at the moment of matching. Transfusions were not guided by coagulation tests. Statistical analysis was performed from June 2018 to June 2019.

EXPOSURES Transfusion of plasma during the first 60 minutes of persistent PPH vs no or later plasma transfusion.

MAIN OUTCOMES AND MEASURES Incidence of adverse maternal outcomes, defined as a composite of death, hysterectomy, or arterial embolization.

RESULTS This study included 1216 women (mean [SD] age, 31.6 [5.0] years) with persistent PPH, of whom 932 (76.6%) delivered vaginally and 780 (64.1%) had PPH caused by uterine atony. Seven women (0.6%) died because of PPH, 62 women (5.1%) had a hysterectomy, and 159 women (13.1%) had arterial embolizations. Among women who received plasma during the first 60 minutes of persistent PPH, 114 women could be matched with a comparable woman who had not received plasma at the moment of matching. The incidence of adverse maternal outcomes was similar between the women, with adverse outcomes recorded in 24 women (21.2%) who received early plasma transfusion and 23 women (19.9%) who did not receive early plasma transfusion (odds ratio, 1.09; 95% CI, 0.57-2.09). Results of sensitivity analyses were comparable to the primary results.

CONCLUSIONS AND RELEVANCE In this cohort study, initiation of plasma transfusion during the first 60 minutes of persistent PPH was not associated with adverse maternal outcomes compared with no or later plasma transfusion, independent of severity of PPH.

Original languageEnglish
Article number1915628
Number of pages16
JournalJama network open
Issue number11
Publication statusPublished - Nov 2019



Cite this